Androgen deprivation therapy (ADT) plays a central role in the management of men with locally advanced, recurrent, and metastatic prostate cancer. Because most men diagnosed with prostate cancer will die of something other than their cancer, treatment-related adverse effects are highly relevant to their long-term health. Benefits of ADT in each clinical setting must be weighed against ADT-related adverse effects. ADT is detrimental to several metabolic end points and to bone health. ADT has been prospectively shown to cause decreased lean muscle mass, increased fat mass, weight gain, increased cholesterol and triglycerides, insulin resistance, and loss of bone mineral density. In population-based analyses it has been associated with an increased incidence of diabetes, clinical fractures, and cardiovascular disease. Data-driven recommendations for managing these adverse effects are needed. Currently the authors advocate the use of adapted practice guidelines developed to prevent diabetes, fractures, and coronary heart disease in the general population.
Correspondence: Philip J. Saylor, MD, Division of Hematology-Oncology, Massachusetts General Hospital, Lawrence House/POB 2nd Floor, 55 Fruit Street, Boston, MA 02114. E-mail: email@example.comDisclosure: Phillip J. Saylor, MD, has disclosed no relevant financial relationships.Disclosure: Matthew R. Smith, MD, PhD, has disclosed the following relevant financial relationships: Served as a consultant for: Amgen Inc.; GTx, Inc.